General Child Neurology
Acute cerebellar ataxia in children
Oct. 29, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Atypical teratoid/rhabdoid tumors
- Updated 03.21.2024
- Released 04.29.2003
- Expires For CME 03.21.2027
Atypical teratoid/rhabdoid tumors
Introduction
Overview
Atypical teratoid/rhabdoid tumor (ATRT) is a highly malignant brain tumor that typically affects young children. Once considered uniformly fatal, intensive multimodal treatment regimens have resulted in improved survival for some patients. The Children’s Oncology Group (COG) published the largest series of prospectively treated patients with atypical teratoid/rhabdoid tumor, demonstrating significantly improved survival for patients younger than 3 years of age compared to historical cohorts. Atypical teratoid/rhabdoid tumor is the first pediatric brain tumor for which a candidate tumor suppressor gene, SMARCB1, was identified. Gene expression profiling analysis suggests that there are three to four distinct molecular subtypes of atypical teratoid/rhabdoid tumors, each with distinct clinic-pathological characteristics.
Key points
|
• Intensive multimodal therapy has improved the outcomes of patients with atypical teratoid/rhabdoid tumors. | |
|
• A somatic mutation of the SMARCB1 or SMARCA4 gene is found in nearly all atypical teratoid/rhabdoid tumors, and an immune-histochemical stain for the gene product can help pathologists readily identify the tumor. | |
|
• Patients with germline mutations for the SMARCB/SMARCA4 gene may have synchronous tumors, and their disease may behave more aggressively. | |
|
• ATRT appears to contain three to four subgroups with distinct epigenomic, transcriptional, and clinic-pathologic features. | |
|
• Studies that incorporated targeted biological therapies to treat atypical teratoid/rhabdoid tumors are underway. |
Historical note and terminology
Atypical teratoid/rhabdoid tumor of the central nervous system is a rare, highly malignant disease that occurs primarily in young children. The disease is often simply referred to as ATRT. It was first identified by Rorke and colleagues as a unique tumor type in 1987. Before that time, patients with atypical teratoid/rhabdoid tumor were often misdiagnosed as having medulloblastoma or other embryonal tumor. This is understandable as approximately two thirds of atypical teratoid/rhabdoid tumors have components that resemble medulloblastoma or other embryonal tumors (42). In addition to rhabdoid cells, atypical teratoid/rhabdoid tumors often contain malignant epithelial and mesenchymal components that further distinguish them from medulloblastoma or other embryonal tumors. Because it histologically resembles the rhabdoid tumor of the kidney, atypical teratoid/rhabdoid tumor was sometimes referred to as malignant rhabdoid tumor of the brain or central nervous system (17) before it was recognized as a distinct entity. The World Health Organization began classifying atypical teratoid/rhabdoid tumor as embryonal grade IV neoplasm in 1993 (32).
Work by Biegel and colleagues identified recurrent deletions/translocations of chromosome 22 as characteristic cytogenetic abnormality in the majority of atypical teratoid rhabdoid tumors (05). The deletions target the SMARCB1 gene in chromosome band 22q11.2, which demonstrates biallelic mutations, deletions, or intragenic duplications in up to 98% of atypical teratoid rhabdoid tumors (06).
Several names are given to the mutated gene in atypical teratoid rhabdoid tumor. It is referred to here as SMARCB1, as this is now its official Human Genome Organization (HUGO) name (31). Other names used for this gene are SNF5, INI-1, and BAF47; they all refer to the same gene or encoding protein.
In 2014, Hasselblatt and colleagues demonstrated that biallelic inactivation of SMARCA4 (or it’s protein BRG-1) was associated with somatic and germline alterations in patients with atypical teratoid/rhabdoid tumor and rhabdoid tumor predisposition syndrome (RTPS), further expanding the diagnostic criteria for atypical teratoid/rhabdoid tumor (23).
Since the description of BAF47/INI1 protein expression using immunostaining (30; 29), atypical teratoid/rhabdoid tumors have been increasingly recognized and frequently diagnosed (52).
Clinical manifestations
Presentation and course
|
• Short history of progressive neurologic changes and symptoms of hydrocephalus should lead the clinician to evaluate for a malignant brain tumor. |
As is the case with other brain tumors, patients with atypical teratoid/rhabdoid tumor present with signs and symptoms that reflect the location of the tumor. Approximately half of atypical teratoid/rhabdoid tumors arise in the posterior fossa (40). Young patients with posterior fossa tumors usually present with symptoms related to hydrocephalus, namely early morning headaches, vomiting, and lethargy. They may also develop ataxia or regression of motor skills. Cranial nerve palsies, particularly VI and VII, are not uncommon. Because young children have open sutures and fairly pliable skulls, a rapidly enlarging head size should alert the practitioner to evaluate the patient for a brain mass as this may be the only symptom at presentation. Patients with supratentorial tumors can present with signs and symptoms of hydrocephalus, enlarging head size, hemiparesis, seizures, or visual changes depending of the location of the tumors. Because atypical teratoid/rhabdoid tumor is a highly malignant tumor, patients typically have a fairly short history of progressive symptoms measured in days to weeks. It is unusual for symptoms to have been present for more than a few months. No data support that clinical characteristics can separate atypical teratoid/rhabdoid tumors from other malignant brain tumors.
Imaging characteristics are also helpful but nonspecific for atypical teratoid/rhabdoid tumor areas of necrosis, hemorrhage, and associated perilesional edema. On T1-weighted imaging, the tumor mass is typically isointense with frequent hyperintense foci secondary to intratumoral hemorrhage. These tumors are highly cellular; therefore, they are hypointense in T2-weighted sequences and demonstrate diffusion restriction in most cases (50). MR spectroscopy findings were similar to other embryonal tumors with marked elevation of choline and low or absent N-acetyl-aspartate and creatine.
On imaging, supratentorial atypical teratoid/rhabdoid tumors are characterized by a thick, wavy, and heterogeneously enhancing wall; hence, imaging is useful when differentiating atypical teratoid/rhabdoid tumors from other entities (02). Additionally, Koral and colleagues reported that tumors located within the cerebellopontine angle (CPA), particularly those presenting with intertumoral hemorrhage, are more likely to correspond to atypical teratoid/rhabdoid tumors than medulloblastomas (33).
Although clinical and radiographic findings can suggest atypical teratoid/rhabdoid tumor, the diagnosis is made pathologically. Loss of immune expression of the SMARCB1 (protein: INI-1) is highly specific for the diagnosis of atypical teratoid/rhabdoid tumor (30). Epithelial membrane antigen (EMA), vimentin, and smooth-muscle actin (SMA) immunopositivity are also commonly seen. A minority of cases (1% to 2%) present with retained INI-1 expression and Brahma-related gene 1 (BRG-1) negativity due to pathogenic mutations in SMARCA4 (23).
The diagnosis of atypical teratoid/rhabdoid tumor should be considered as part of the differential diagnosis of young children, especially when the child is less than 3 years of age presenting with a malignant brain tumor.
Prognosis and complications
The prognosis for patients with atypical teratoid/rhabdoid tumors has improved over the last decades after increased recognition as a distinct entity and the development of atypical teratoid/rhabdoid tumor-specific approaches.
Nevertheless, the prognosis of these patients remains guarded, particularly in the younger patients.
Clinical vignette
A 13-year-old previously healthy female presented to the emergency department with a 1-month history of progressive worsening headaches, and over the week before presentation, the headaches were associated with early morning emesis. She had no vision changes, focal neurologic deficits, or gait disturbances. She was initially treated symptomatically with pain medication; due to the lack of symptomatic improvement, brain imaging was performed. MRI of the brain demonstrated a large solid and cystic lesion located in the right frontal lobe measuring 5.4 cm x 6.1 cm. The mass was partially hemorrhagic and demonstrated diffusion restriction on diffusion-weighted imaging of the spine and did not demonstrate evidence of disseminated disease.
The patient underwent a gross total tumor resection; she tolerated the procedure well and had no neurologic deficits postoperatively.
Histopathological examination demonstrated a markedly hypercellular neoplasm with nuclear enlargement and prominent nucleoli. Immunohistochemistry showed negativity for GFAP, olig2, S100, and synaptophysin. INI-1 expression was lost in the tumor cells, supporting the diagnosis of atypical teratoid/rhabdoid tumor. Methylation profiling classified this tumor as an ATRT-MYC subgroup.
Staging workup was negative for disseminated disease, and renal ultrasound showed normal kidneys without a renal mass.
The patient was formally enrolled and treated in a therapeutic trial that included craniospinal proton irradiation (CSI) 23.4 Gy and tumor bed boost to a total dose of 54 Gy; she received consolidation chemotherapy with five cycles of intensive chemotherapy with cyclophosphamide, cisplatin, vincristine, and an Aurora kinase inhibitor (Alisertib). Finally, she received six cycles of maintenance of alisertib. Currently, the patient is off therapy without evidence of disease and will continue under close clinical and radiological surveillance.
Biological basis
|
• Atypical teratoid/rhabdoid tumors are characterized by biallelic inactivation of SMARCB1 (common) or SMARCA4 (rare). | |
|
• Approximately 20% to 30% of patients with atypical teratoid/rhabdoid tumors have underlying SMARCB1 or SMARCA4 germline alterations. |
Etiology and pathogenesis
Pathology. Atypical teratoid/rhabdoid tumor is recognized as a distinct clinical entity because of its pathologic and genetic characteristics. Histologically, atypical teratoid/rhabdoid tumor contains sheets of rhabdoid cells against a background of primitive neuroectodermal cells, mesenchymal cells, or epithelial cells. Some tumors are composed entirely of rhabdoid cells, whereas others show a combination of rhabdoid cells and areas resembling primitive neuroectodermal tumor or medulloblastoma. Immunohistochemical features help to identify the disease but vary depending on the cellular composition of the tumor. Rhabdoid cells express vimentin and epithelial membrane antigen, neurofilament, glial fibrillary acidic protein, and keratin. The primitive neuroectodermal cells may express neurofilament protein, glial fibrillary acidic protein, or desmin. These rapidly growing tumors can have K-67 labeling indices of 50% to 100% (32). Finally, the cardinal immunohistochemical finding for diagnosis is the loss of expression of INI-1 or BRG-1 (30).
Pathogenesis and molecular subgrouping. Atypical teratoid/rhabdoid tumors are molecularly characterized by biallelic inactivation of the SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) or, in rare cases subfamily a, member 4 (SMARCA4).
Epigenetic dysregulation has been postulated as the main mechanism of oncogenesis in this entity. The loss of a member of the chromatin remodeling SNF/SWF complex, INI-1 or BRG-1, increases the expression and activity of polycomb repressive complexes (PRCs), thereby activating the histone methyl transferase enhancer of zeste homolog 2 (EZH2) downstream oncogenic pathways (36; 27).
Studies postulate that different residual INI-1-deficient SWI/SNF complexes are associated with the activation of different lineage-related pathways, accounting for the oncogenic phenotypes observed in atypical teratoid/rhabdoid tumors (38; 49). This discovery led to the molecular classification of atypical teratoid/rhabdoid tumor, which established three molecular subgroups: ATRT-SHH, ATRT-TYR, and ATRT-MYC (26; 47; 28).
|
(1) ATRT-SHH (group 1): Characterized by neuronal differentiation. This subgroup is characterized by the overexpression of the SHH and NOTCH pathways. Approximately 50% of the tumors in this subgroup have point mutations in SMARCB. The median age of presentation of patients in this subgroup is of approximately 2 years and 75% of ATRT-SHH tumors present as supratentorial lesions (26). | |
|
(2) ATRT- TYR (group 2A): the ATRT-TYR subgroup is characterized by overexpression of tyrosinase and melanin metabolism pathways genes, suggesting a neuroectodermal origin. Large deletions of chromosome 22 are the characteristic SMARCB1 alterations of this group. Most patients with ATRT-TYR tumors present with infratentorial lesions (75%) and are the youngest group of patients (median age at diagnosis of 12 months) (26). | |
|
(3) ATRT-MYC (group 2B): These tumors are distinguished by a mesenchymal expression profile with MYC overexpression. Homozygous broad loss of SMARCB1 is the most frequent alteration seen in this group. Most ATRT-MYC patients are older, with a median age at diagnosis of 2.5 years. The most common tumor location in this subgroup is in the supratentorial region, and spinal ATRTs belong to this molecular subgroup (26). |
The prognostic significance of these subgroups remains unclear (20; 41), and additional studies are underway to better understand the subgroup-specific therapeutic susceptibilities.
Epidemiology
Atypical teratoid/rhabdoid tumor was initially thought to be extraordinarily rare. With increased clinical awareness of this tumor and the utility of the immunohistochemistry assay for SMARCB1 (INI-1), it is now estimated that atypical teratoid/rhabdoid tumor accounts for at least 3% of brain tumors in children. All published series report a peak incidence in very young children, less than 3 years of age. Based on prior Children’s Cancer Group, Pediatric Oncology Group, and Pediatric Brain Tumor Consortium studies. Atypical teratoid/rhabdoid tumors account for approximately 20% of brain tumors in children less than 3 years of age (35; 52; 35; 24). In an Austrian study of 311 newly diagnosed tumors, atypical teratoid/rhabdoid tumor was the sixth most common entity (6.1%) (52). The number of reported patients with atypical teratoid/rhabdoid tumor has increased 5.5-fold in an analysis of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data from 1992 to 2008, likely reflecting greater awareness and improved diagnostic techniques. The Central Brain Tumor Registry of the United States (CBTRUS) reported an age-adjusted incidence rate of 0.9 per million children between the ages of 0 to 19 years from 2012 to 2016 (39). Although it is much less common in older children and adults, atypical teratoid/rhabdoid tumor has been reported with increasing frequency in these populations as well.
Prevention
There is no known means to prevent the development of an atypical teratoid rhabdoid tumor. In patients harboring germline SMARCB1 (RTPS1) or SMARCA4 (RTPS2) mutations, surveillance imaging with whole-body MRIs (WBMRI) and brain/spine MRIs have been recommended, with the objective to diagnose tumors at a stage on which complete resection is still possible (21).
Differential diagnosis
The rhabdoid tumor predisposition syndromes (RTPS1 and 2) are rare genetic conditions characterized by germline truncating pathogenic variants in SMARCB1 (RTPS1) or SMARCA4 (RTPS2) genes. Those affected by the condition have an increased risk of developing rhabdoid tumors (intra and extracranially) (44; 34; 07; 15).
Rhabdoid tumor predisposition syndrome is inherited in an autosomal dominant manner. Although most cases occur de novo, in rare cases, individuals inherit a pathogenic variant from an unaffected parent.
It is estimated that 20% to 35% of patients diagnosed with atypical teratoid/rhabdoid tumors across all age groups have an associated deleterious germline alteration (04). Nevertheless, there is a wide variation among different studies. The published ACNS0333 study only identified a pathogenic germline mutation in 17% of patients in their cohort (41). In contrast, Fossey and colleagues reported a higher proportion of patients (83.3%) diagnosed with atypical teratoid/rhabdoid tumor in the first year of life, carrying a pathogenic mutation in SMARCB1 (18).
Although the prognostic significance of germline alterations in patients with atypical teratoid/rhabdoid tumor remains to be elucidated, it provides useful information for counseling and surveillance purposes (19; 21). The recommendation is to offer germline testing and genetic counseling to all patients diagnosed with atypical teratoid/rhabdoid tumors.
Confusing conditions
Atypical teratoid/rhabdoid tumor may be difficult to distinguish from other embryonal tumors, particularly medulloblastoma. Before atypical teratoid/rhabdoid tumor was widely recognized, many were misdiagnosed as such (42; 08). Other malignant nervous system tumors should also be considered in the differential diagnosis, including embryonal tumors with multilayer rosettes (ETMRs), pineoblastomas, choroid plexus carcinomas, and ependymoma. High-grade glial neoplasms can occur in young children but are extremely rare.
Diagnostic workup
Patients with suspected atypical teratoid/rhabdoid tumor should undergo complete MRI imaging of the brain and spine prior to surgery unless emergent surgery precludes this being done. This is to quantify the radiographic extent of disease at diagnosis and is necessary for conformal radiation planning. Surgical resection is indicated for nearly all patients with atypical teratoid/rhabdoid tumor; this is for both diagnosis and treatment. The tumor should undergo pathologic and molecular genetic testing. Methylation profiling should be considered if adequate tumor is available. A lumbar puncture should be performed as part of the staging evaluation to assess for cerebrospinal fluid dissemination. The cerebrospinal fluid evaluation should be completed at least 14 days after surgery to reduce the probability of false-positive results (37).
Patients with new diagnosis of atypical teratoid/rhabdoid tumor should undergo a renal ultrasound to rule out the possibility of synchronous tumors.
Management
|
• Regimens that include intensive multi-modal therapies improve survival. | |
|
• Targeted pathway inhibitors and other novel therapies are urgently needed. |
Treatment of atypical teratoid/rhabdoid tumor has often paralleled that of infant medulloblastoma or other embryonal tumors. Early trials by the Pediatric Oncology Group POG) 9233/4 and Children’s Cancer Group (CCG) 9921 treated very young children diagnosed with various embryonal brain tumors, including atypical teratoid/rhabdoid tumors with multi-agent chemotherapy, resulting in poor outcomes (22; 45). Multimodal therapeutic approaches have improved the survival of these patients (25; 10; 48; 35; 03). The standard of care includes a combination of maximal safe resection, chemotherapy, and radiation therapy.
Surgery. Surgical resection is an important component in the management of atypical teratoid/rhabdoid tumors. However, due to the invasive nature of these tumors, gross total resection (GTR) is only possible in approximately 30% to 68% of cases (46; 10; 14; 35). Some studies have suggested a survival advantage in patients undergoing a gross total resection (10); however, other studies failed to demonstrate a prognostic effect (46; 01; 43).
Contemporary data from the ACNS0333 trial demonstrated that the extent of surgical resection did not impact survival when part of an intensified multimodal approach including high-dose chemotherapy (HDC) and radiotherapy (RT) (41). Likewise, the European Rhabdoid Registry (EU-RHAB) reported the outcomes of 143 patients uniformly treated using either radiotherapy or high-dose chemotherapy (20); akin to the North American results, complete surgical resection was not identified as a prognostic factor in association with other therapeutic modalities. These data suggest a maximal safe surgical resection should continue to be sought after in patients with atypical teratoid/rhabdoid tumor.
Chemotherapy. Given the young age of most patients with atypical teratoid/rhabdoid tumor, chemotherapy has been the main form of postsurgical adjuvant therapy. Varieties of chemotherapeutic approaches have been utilized with varying success. Many patients have also been treated with radiation, adding further complexity to evaluating the efficacy of a given chemotherapy regimen. Outcomes for children treated with surgery and standard chemotherapy alone are extremely poor.
Legacy cooperative group “baby brain” protocols employed dose-intensified multi-agent chemotherapy to treat a variety of malignant brain tumors in very young children POG 9233/4 and CCG 9921 enrolled 63 patients with atypical teratoid/rhabdoid tumor and achieved a 24-months event-free survival (EFS) of 6.4% (22; 45). In both studies, however, early responses to chemotherapy were seen.
Chi and colleagues published the results of the first prospective trial using the backbone of the Intergroup Rhabdomyosarcoma Study protocol III (IRS-III) and modified it to include intrathecal chemotherapy (10). The study resulted in a 58% response rate before radiation therapy, suggesting a survival benefit using intensified multimodal therapy.
High-dose chemotherapy was adopted as a radiotherapy deferral/avoidance approach (25; 10; 16; 35). Hilden and colleagues reported their experience using high-dose chemotherapy in patients with atypical teratoid/rhabdoid tumor, demonstrating 46% of patients who received high-dose chemotherapy were survivors (25). Furthermore, Cohen and colleagues reported the outcomes of eight patients with atypical teratoid/rhabdoid tumor treated in the CCG99703 study, demonstrating a 5-year event-free survival of 37.5% (12).
The COG-ACNS0333 study incorporated high-dose methotrexate to the CCG99703 chemotherapy backbone followed by consolidation therapy with three tandem cycles of HDC with carboplatin and thiotepa conditioning with stem cell rescue and radiotherapy. Sixty-five evaluable patients had a 4-year event-free survival and overall survival (OS) of 37% and 43%, respectively (41).
The European Rhabdoid Registry (EU-RHAB) reported the outcomes of 143 patients uniformly treated using either radiotherapy or high-dose chemotherapy and reported a 5-year event-free survival and overall survival of 30.5% and 34.7%, respectively (20).
Radiation therapy appears to be an important component of therapy for atypical teratoid/rhabdoid tumor patients. Several studies have demonstrated a survival advantage in patients with atypical teratoid/rhabdoid tumor treated with radiotherapy. Tekautz and colleagues published the outcomes of nine children over the age of 3 years treated with craniospinal irradiation (CSI) in addition to high-dose chemotherapy as part of their initial treatment (46). A 3-year event-free survival of 78% was reported.
Buscariollo and colleagues identified 144 patients with atypical teratoid/rhabdoid tumor in the National Cancer Institute’s Surveillance, Epidemiology, and End Results Database (09). The study confirmed a robust association between radiation therapy use and survival.
ACNS0333 led to significantly improved survival and confirms that some patient with atypical teratoid/rhabdoid tumor can be cured of their disease with intensive multimodal regimens that include high-dose chemotherapy with peripheral blood stem cells and radiation.
Proton beam radiation may have an advantageous role in treating atypical teratoid/rhabdoid tumors. A series of very young patients treated with proton beam reported good disease control and increased sparing of healthy tissues, such as cerebrum, temporal lobe, cochlea, and hypothalamus (13).
Future directions. Approximately half of the patients will unfortunately succumb to the disease despite the use of multimodal approaches. The improved understanding of the biological underpinnings of atypical teratoid/rhabdoid tumor will result in the identification of new therapeutic targets.
Atypical teratoid/rhabdoid tumors are a disease of epigenetic dysregulation mediated by the loss of SMARCB1 (51). The defective polycomb repressive complex (PCR) leads to increased expression and activity of the histone methyl transferase enhancer of zeste homolog 2 (EZH2) (51; 38). In-vitro studies have demonstrated that cell lines derived from ATRT-SHH tumors are particularly sensitive to EZH2 inhibition (47); hence, a phase I trial for SMARCB1-deficient tumors is underway (NCT02601937).
Preclinical data suggest atypical teratoid/rhabdoid tumor may be a good candidate for pathway-specific therapies. Several preclinical studies have shown promising results. Analyses demonstrated upregulation of platelet-derived growth factor receptor B (PDGFRB) in ATRT-MYC and ATRT-TYR cell lines and xenografts. Dasatinib and nilotinib produced significant in vitro and in vivo cytotoxicity (47). Although further studies are required to validate these observations, the findings provide promising targets for future studies.
Furthermore, studies have improved our understanding of the immune microenvironment in ATRT. Chun and colleagues demonstrated ATRT-MYC tumors had significantly greater CD8+ T-cell infiltration than tumors in the TYR/SHH subgroups (11). Several clinical trials using immunotherapy for ATRT are ongoing.
The progress made toward understanding tumor biology will facilitate the development of novel, risk-stratified, and biologically informed therapeutic approaches.
Media
References
- 01
- Athale UH, Duckworth J, Odame I, Barr R. Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J Pediatr Hematol Oncol 2009;31(9):651-63. PMID 19707161
- 02
- Au Yong KJ, Jaremko JL, Jans L, et al. How specific is the MRI appearance of supratentorial atypical teratoid rhabdoid tumors? Pediatr Radiol 2013;43(3):347-54. PMID 23143401
- 03
- Bartelheim K, Nemes K, Seeringer A, et al. Improved 6-year overall survival in AT/RT—Results of the registry study Rhabdoid 2007. Cancer Med 2016;5(8):1765-75. PMID 27228363
- 04
- Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet 2014;166C(3):350-66. PMID 25169151
- 05
- Biegel JA, Rorke LB, Emanuel BS. Monosomy 22 in rhabdoid or atypical teratoid tumors of the brain. N Engl J Med 1989;321:906. PMID 2770830
- 06
- Bourdeaut F, Chi SN, Fruhwald MC. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013. Cancer Genet 2014;207(9):346-51. PMID 25468731
- 07
- Bourdeaut F, Lequin D, Brugieres L, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res 2011;17:31-8. PMID 21208904
- 08
- Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol 1998;22(9):1083-92. PMID 9737241
- 09
- Buscariollo DL, Park HS, Roberts KB, Yu JB. Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 2012;118(17):4212-9.** PMID 22213196
- 10
- Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clinc Oncol 2009;27(3):385-9. PMID 19064966
- 11
- Chun HJ, Johann PD, Milne K, et al. Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration. Cell Rep 2019;29(8):2338-54.e7. PMID 31708418
- 12
- Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children’s Oncology Group. Pediatr Neurol 2015;53(1):31-46. PMID 26092413
- 13
- De Amorim Bernstein K, Sethi R, Trofimov A, et al. Early clinical outcomes using proton radiation for children with central nervous system atypical teratoid rhabdoid tumors. Int J Radiat Oncol Biol Phys 2013;86(1):114-20. PMID 23498870
- 14
- Dufour C, Beaugrand A, Le Deley MC, et al. Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system: a multicenter study. Cancer 2012;118(15):3812-21. PMID 22180295
- 15
- Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011;56(1):7-15. PMID 21108436
- 16
- Finkelstein-Shechter T, Gassas A, Mabbott D, et al. Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol 2010;32(5):e182-6. PMID 20495479
- 17
- Fisher BJ, Siddiqui J, Macdonald D, et al. Malignant rhabdoid tumor of brain: an aggressive clinical entity. Can J Neurol Sci 1996;23(4):257-63. PMID 8951203
- 18
- Fossey M, Li H, Afzal S, et al. Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. J Neurooncol 2017;132(1):155-62. PMID 28102486
- 19
- Foulkes WD, Kamihara J, Evans DGR, et al. Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. Clin Cancer Res 2017;23(12):e62-e7. PMID 28620006
- 20
- Fruhwald MC, Hasselblatt M, Nemes K, et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro Oncol 2020;22:1006-17. PMID 31883020
- 21
- Frühwald MC, Nemes K, Boztug H, et al. Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Fam Cancer 2021;20:305-16. PMID 33532948
- 22
- Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005;23(30):7621-31. PMID 16234523
- 23
- Hasselblatt M, Nagel I, Oyen F, et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathol 2014;128(3):453-6. PMID 25060813
- 24
- Heck JE, Lombardi CA, Cockburn M, Meyers TJ, Wilhelm M, Ritz B. Epidemiology of rhabdoid tumors of early childhood. Pediatr Blood Cancer 2013;60(1):77-81. PMID 22434719
- 25
- Hilden JM, Meerbaum S, Burger P, et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J Clin Oncol 2004;22(14):2877-84. PMID 15254056
- 26
- Ho DM, Hsu CY, Wong TT, Ting LT, Chiang H. Atypical teratoid/rhabdoid tumor of the central nervous system: a comparative study with primitive neuroectodermal tumor/medulloblastoma. Acta Neurolpathol 2000;99(5):482-8. PMID 10805090
- 27
- Hoffman LM, Richardson EA, Ho B, et al. Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro Oncol 2020;22(7):944-54. PMID 32129445
- 28
- Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 2016;29(3):379-93. PMID 26923874
- 29
- Judkins AR, Burger CP, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropath Experl Neurol 2005;64:391-7.
- 30
- Judkins AR, Mauger J, Rorke LB, and Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 2004;28(5):644-50.** PMID 15105654
- 31
- Kim KH, Roberts CW. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 2014;207(9):365-72. PMID 24853101
- 32
- Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215-25; discussion 226-9. PMID 11895036
- 33
- Koral K, Mathis D, Gimi B, et al. Common pediatric cerebellar tumors: correlation between cell densities and apparent diffusion coefficient metrics. Radiology 2013;268(2):532-7. PMID 23564715
- 34
- Kordes U, Gesk S, Fruhwald MC, et al. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer 2010;49(2):176-81. PMID 25415685
- 35
- Lafay-Cousin L, Hawkins C, Carret AS, et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 2012;48(3):353-9. PMID 22023887
- 36
- Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012;122(8):2983-8. PMID 22797305
- 37
- Meyers SP, Wildenhain SL, Chang JK, et al. Postoperative evaluation for disseminated medulloblastoma involving the spine: contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient outcomes. AJNR Am J Neuroradiol 2000;21(9):1757-65. PMID 11039362
- 38
- Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet 2017;49(11):1613-23. PMID 28945250
- 39
- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. (2020). CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol 2020;22(12 Suppl 2):iv1-iv96. PMID 33123732
- 40
- Packer RJ, Biegel JA, Blaney S, at al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol 2002;24(5):337-42.** PMID 12142780
- 41
- Reddy AT, Strother DR, Judkins AR, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children’s Oncology Group Trial ACNS0333. J Clin Oncol 2020;38(11):1175-85. PMID 32105509
- 42
- Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J Neurosurg 1996;85(1):56-65. PMID 8683283
- 43
- Schrey D, Carceller Lecho´n F, Malietzis G, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol 2016;126(1):81-90. PMID 26608522
- 44
- Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999;1342-8. PMID 10521299
- 45
- Strother DR, Lafay-Cousin L, Boyett JM, et al. Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/4. Neuro Oncol 2014;16(3):457-65. PMID 24335695
- 46
- Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005;23(7):1491-9. PMID 15735125
- 47
- Torchia J, Picard D, Lafay-Cousin L, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 2015;16(5):569-82.** PMID 25882982
- 48
- von Hoff K, Hinkes B, Dannenmann-Stern E, et al. Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database. Pediatr Blood Cancer 2011;57(6):978-85. PMID 21796761
- 49
- Wang X, Lee RS, Alver BH, et al. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Gen 2017;49(2):289-95. PMID 27941797
- 50
- Warmuth-Metz M, Bison B, Dannemann-Stern E, Kortmann R, Rutkowski S, Pietsch T. CT and MR imaging in atypical teratoid/rhabdoid tumors of the central nervous system. Neuroradiology 2008;50(5):447-52. PMID 18345534
- 51
- Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010;18(4):316-28. PMID 20951942
- 52
- Woehrer A, Slavc I, Waldhoer T, et al. Incidence of atypical teratoid/rhabdoid tumors in children: a population-based study by the Austrian Brain Tumor Registry, 1996-2006. Cancer 2010;116(24):5725-32. PMID 20737418
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Adriana Fonseca MD
Dr. Fonseca Sheridan of Children's National Hospital and George Washington University has no relevant financial relationships to disclose.
See Profile
Editor
-
Roger J Packer MD
Dr. Packer of Children’s National Medical Center and George Washington University has no relevant financial relationships to disclose.
See Profile
Former Authors
- Alyssa Reddy MD
Patient Profile
- Age range of presentation
-
- 0 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor for rhabdoid tumor predisposition syndrome
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Malignant neoplasm of cerebellum nos: 191.6
- ICD-10
-
- Atypical teratoid rhabdoid tumor: C72.9
- OMIM
-
- Rhabdoid tumors: #609322
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuro-Oncology
Overview of neuropathology updates for infiltrating gliomas
Oct. 11, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
General Child Neurology
Cerebral edema in childhood
Sep. 29, 2024
-
Neuro-Oncology
CNS germinoma
Sep. 25, 2024
-
Developmental Malformations
Vein of Galen malformations
Sep. 22, 2024
-
Neuro-Oncology
Vestibular schwannoma
Sep. 19, 2024